Renalytix Highlights Study Results For Co.’s KidneyIntelX Published In ‘The American Journal Of Nephrology,’ Showed ‘KidneyIntelX successfully monitors patient response to SGLT2 therapy in 1,325 CANagliflozin CardioVAScular Assessment…’
Renalytix (NASDAQ:RNLX) (LSE: RENX) announced the publication of positive study results for KidneyIntelX™ as a risk monitoring tool to assess impact and response to novel treatments for patients with
BTIG Initiates Coverage On Renalytix with Buy Rating, Announces Price Target of $24
BTIG analyst Mark Massaro initiates coverage on Renalytix (NASDAQ:RNLX) with a Buy rating and announces Price Target of $24.
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck’s HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For December 7, 2021
Companies Reporting Before The Bell
• Core & Main (NYSE:CNM) is expected to report quarterly earnings at $0.30 per share on revenue of $1.29 billion.
Earnings Scheduled For October 21, 2021
Companies Reporting Before The Bell
• Tri Pointe Homes (NYSE:TPH) is estimated to report quarterly earnings at $0.89 per share on revenue of $946.97 million.
46 Biggest Movers From Yesterday
Gainers
Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share.